The Patent Finder
AM

Amgen Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

1,246 patents currently held

84 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
243
Ending by 2030
Dec 2026
Next term end
753
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) US 8,030,457
Cited by 236 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Ends May 2030 · High confidence Also notable
Drive Mechanism for Drug Delivery Pumps with Integrated Status Indication US 9,814,832
Cited by 142 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Ends Jan 2034 · High confidence Also notable
Autoinjector Apparatus US 10,092,706
Cited by 151 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Ends Dec 2033 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 19 fees due Dec 2 to 30, 2026 · next Dec 2
  • 16 fees due Jan 2 to 28, 2027 · next Jan 2
  • 11 fees due Feb 4 to 28, 2027 · next Feb 4
  • 23 fees due Mar 3 to 29, 2027 · next Mar 3
  • 10 fees due Apr 1 to 30, 2027 · next Apr 1
  • 19 fees due May 3 to 28, 2027 · next May 3
  • 15 fees due Jun 1 to 30, 2027 · next Jun 1
  • 21 fees due Jul 2 to 30, 2027 · next Jul 2
  • 13 fees due Aug 4 to 25, 2027 · next Aug 4
  • 21 fees due Sep 1 to 29, 2027 · next Sep 1
  • 24 fees due Oct 2 to 30, 2027 · next Oct 2
  • 9 fees due Nov 3 to 12, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The 5 largest of its 753 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione:, and Methods of Synthesis and Compositions Thereof26 in forceto Oct 2036
Insertion Mechanism for a Drug Delivery Pump15 in forceto Jan 2035
Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)14 in forceto Nov 2030
Injector and Method of Assembly11 in forceto Jan 2034
Autoinjector Apparatus10 in forceto May 2040

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 8,002,745Retractable Syringe with Plunger Disabling System
In force
 · High confidence
In forceHigh confidence
US 8,680,248Host Cells Comprising Alpha 1, 2 Mannosidase and Culture Methods Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,273,110Production of Glycoproteins Using Manganese
In force
 · Medium confidence
In forceMedium confidence
US 12,351,613Production of Glycoproteins Using Manganese
In force
 · Medium confidence
In forceMedium confidence
US 11,267,900Antibodies Directed to HER-3 and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 8,614,292An isolated protein comprising an activin type IIB5 receptor polypeptide and uses thereof
In force
 · High confidence
In forceHigh confidence
US 7,514,566Thiazole Compounds and Methods of Use
In force
 · High confidence
In forceHigh confidence
US RE45,847Antibodies to Madcam
In force
 · Low confidence
In forceLow confidence
US 7,928,205Methods for Refolding of Recombinant Antibodies
In force
 · High confidence
In forceHigh confidence
US 10,072,090Human Anti-B7RP1 Neutralizing Antibodies
In force
 · High confidence
In forceHigh confidence
10 of 1,246 patents shown.
Pro members see all 1,246.
Pro members: see all 1,246 patents
Also on record, not counted in the 1,246: 84 patents in force now held by others · 442 patents ended · 606 applications pending · 632 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Export every term end as CSV · Pro
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited